FindTrial
Sign In

PD-L1 t-haNK

BIOLOGICAL6 trials

Sponsors

ImmunityBio, Inc., National Cancer Institute (NCI), Glenn J. Hanna

Conditions

Advanced HNSCCAdvanced Triple Negative Breast CancerGastroesophageal Junction (GEJ) CancersGlioblastomaHead and Neck CancerHead and Neck Squamous Cell CarcinomaLocally Advanced Solid TumorMetastatic Cancer

Phase 1

QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
CompletedNCT04050709
ImmunityBio, Inc.Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor
Start: 2019-07-18End: 2026-03-25Updated: 2026-04-01
A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies
TerminatedNCT04927884
ImmunityBio, Inc.Advanced Triple Negative Breast Cancer
Start: 2021-09-08End: 2022-12-12Updated: 2024-06-12

Phase 2

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Active, not recruitingNCT04390399
ImmunityBio, Inc.Pancreatic Cancer
Start: 2020-07-21End: 2026-05-31Target: 328Updated: 2025-12-15
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
Active, not recruitingNCT04847466
National Cancer Institute (NCI)Advanced HNSCC, Gastroesophageal Junction (GEJ) Cancers
Start: 2021-12-14End: 2027-12-31Updated: 2025-12-24
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
RecruitingNCT06061809
ImmunityBio, Inc.Glioblastoma
Start: 2024-08-07End: 2030-12-31Target: 34Updated: 2026-02-12
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RecruitingNCT06239220
Glenn J. HannaHead and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer +3
Start: 2024-02-16End: 2027-01-31Target: 25Updated: 2026-02-27

Related Papers

Association of lymphopenia rescue and CA19-9 levels with overall survival following IL-15 superagonist N-803 and PD-L1 t-haNK chemo-immunotherapy for 3 <sup>rd</sup> line or greater metastatic pancreatic cancer.
Journal of Clinical Oncology2025-05-28
Abstract 5255: Systemic immunosuppression in pancreatic cancer
Cancer Research2025-04-21
First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer.
2025-02-1410 citations
Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer
Future Oncology2023-05-185 citations
Phase 2 Quilt 88 trial of DAMP inducers combined with IL15 superagonist, N-803, and anti–PD-L1 NK cell therapy more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer.
Journal of Clinical Oncology2022-06-015 citations
Promising survival and disease control in third-line or greater metastatic or locally advanced pancreatic cancer patients following chemo-radiation and novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy.
Journal of Clinical Oncology2022-01-195 citations
Trial in progress: Open-label, randomized, comparative phase 2/3 study of combination immunotherapy plus standard-of-care chemotherapy and SBRT versus standard-of-care chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer.
Journal of Clinical Oncology2021-05-203 citations
Quilt-3.064: An open-label phase I study of PD-L1 t-haNK in subjects with locally advanced or metastatic solid cancers.
Journal of Clinical Oncology2020-05-207 citations